National University Hospital Inflammatory Bowel Disease (NUH-IBD) Preceptorship Programme

Welcome to the 2025 NUH-IBD Preceptorship Program, designed and delivered by National University Hospital Singapore, and sponsored by Ferring Pharmaceuticals.

In this 5-day NUH-IBD Preceptorship Program, I am certain you will find yourselves among like-minded peers amid state-of-the-art lectures in IBD management featured by novel speaking session. The topics that will be covered in this Preceptorship Program including:

1. IBD Diagnosis
2. Endoscopy, Histology and Radiology in IBD
3. Principles management of IBD (UC and CD)
4. Immunomodulator and Biologic Considerations
5. IBD Complications
6. Surgical Management in IBD
7. IBD in Pregnancy and Paediatrics
8. Diet Management in IBD

In addition to abovementioned comprehensive lectures, there will be also studycase sharing and discussion from participants, IBD clinic attend and NUH Department Tour.

To ensure you derive the best quality learning experience, your diligent participation is highly encouraged. Hence, it is my sincere hope that you will fully leverage on this opportunity to engage and network in this preceptorship program, as well as work together for the best treatment outcomes for our patients.

I hope that you can take your time to fully engage in this Preceptorship Program, make this a lively interactive session and hopefully to bring the knowledge for a better treatment care for your patients.

Thank you for your participation and looking forward to meeting you in Singapore soon!

As the incident rates of inflammatory bowel disease (IBD) sharply increase in Asia , it becomes imperative that treatment goals evolve to retard disease progression, reduce morbidity, and minimize its cost burden. Reflecting the increased disease incidence in Asia as well as newer therapies prolonging survival, we are now faced with the phenomenon of ‘compound prevalence’ , where IBD is poised to become a significant burden on healthcare resource utilization . Therefore, it becomes an urgent need in our region to ensure that IBD patients are optimally treated during the mild-moderate disease phase for prolonged disease remission and prevention of early progression to moderate-severe disease – a stage which is often associated with prohibitive costs.

Therefore, management of IBD must shift beyond symptomatic control, moving towards a treat-to-target (T2T) approach for achieving deep mucosal remission at the early disease stage. Treatment advances have made deep remission a realistic target for some patients with IBD, with a focus on objective parameters such as endoscopic, histological, and biochemical remission . However, achieving deep remission in IBD within our local healthcare settings comes with several challenges unique to Asia. Yet, it is an aspiration that remains significantly important to improve the long-term prognosis of our IBD patients.

NUH-IBD Preceptorship Program is to create a vibrant learning space for SEA IBD experts to understand/update current thinking, challenges in clinical practice, dilemmas in clinical decision making, and educational needs of IBD doctors, through an innovative and structured method of quality medical engagement.

Two-way airport transfers were provided by Ferring for the 2025 programme, including airport pick-up and return transfers.

Participants were requested to look out for a driver holding a card with their name.

Participants were requested to gather at the hotel lobby at 08:30 for transportation to NUH.